Search clinical trials for: BAY94-9343 (Anetumab ravtansine)

Total 16 results

Bayer

Completed

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Neoplasms

France, Moldova, Republic of
Bayer
ImmunoGen and MorphoSys

Completed

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Mesothelioma

Belgium, France, United States, Canada, Spain, Turkey, United Kingdom, Australia, Finland, Italy, Poland, Korea, Republic of, Netherlands, Russian Federation
Bayer

Terminated

A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies

Solid Tumors

United States, Italy, France, Poland
Bayer

Completed

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Oncology

United States
Bayer

Completed

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Ovarian Neoplasms

Belgium, Spain, Moldova, Republic of, United States
National Cancer Institute (NCI)

Terminated

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

Lung Neoplasms

United States
Bayer

Completed

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Neoplasms

Japan
Bayer
ImmunoGen, Inc.; MorphoSys AG

Completed

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)

Neoplasms

United States, Spain, United Kingdom, Korea, Republic of, Canada, France, Belgium, Australia, Singapore, Italy, Netherlands, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Pleural Malignant Mesothelioma

United States, Canada
Bayer

Completed

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Medical Oncology

United States, Belgium, Spain, France, Netherlands, Australia
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Mesothelin Positive

United States
Yale University
Bayer

Completed

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Pancreatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditions

United States, Canada
Gary M Brittenham, MD

Active, not recruiting

Daily Vitamin D for Sickle-cell Respiratory Complications (ViDAS-2)

Respiratory Tract Infections | Respiratory Tract Diseases | Respiration Disorders | Lung Diseases | Nutrition Disorders | Vitamin D Deficiency | Asthma | Sickle Cell Disease | Anemia, Sickle Cell | Anemia, Hemolytic, Congenital | Acute Chest Syndrome | Deficiency Diseases Vitamin

United States
Ulrik Lassen
GlaxoSmithKline; Pfizer; Roche Pharma AG

Recruiting

ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget)

Neoplasms | Cancer | Tumors | Neoplasia

Denmark

Search clinical trials for: BAY94-9343 (Anetumab ravtansine)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations